Point72 Asset Management
CGON icon

Point72 Asset Management’s CG Oncology CGON Stock Holding History

Point72 Asset Management’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$654K Sell
9,200
-16,700
-64% -$1.09M ﹤0.01% 3050
2026
Q1 		$1.75M Buy
+25,900
New +$1.47M ﹤0.01% 2400

Other funds holding CGON

RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Point72 Asset Management's CGON Position: Q2 2026 in Review

Point72 Asset Management sold out of CG Oncology (CGON) in Q2 2026, closing a stake of 399,392 shares — an estimated $26.1M sold.

Point72 Asset Management first reported a position in CGON in Q1 2024 and held it in 9 quarters. The position peaked at $61.4M in Q3 2025. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Point72 Asset Management reported no remaining CG Oncology position as of Q2 2026 after selling out during the quarter.
  • Point72 Asset Management sold 399,392 CG Oncology shares in Q2 2026, an estimated $26.1M.
  • Point72 Asset Management first reported a position in CG Oncology in Q1 2024 and held it in 9 quarters.
  • Point72 Asset Management's CG Oncology position peaked at $61.4M in Q3 2025.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.